Hospital Occupancy
67%
Flat YoY
Occupancy steady despite 14% increase in occupied beds to 3,189.
FORTISHEALTHCARE
Healthcare
30 Jan 2026
Fortis Healthcare Ltd — Q3 FY26
Fortis Healthcare delivered a strong Q3 FY26 with consolidated revenue of ₹2,265 crore (+17.5% YoY) and EBITDA margin expansion of 290 bps to 22.3%, driven by hospital business growth of 19.4% and diagnostics margin recovery to 23.1%.
✓ Verified against BSE filing
2-Min Summary
Fortis Healthcare delivered a strong Q3 FY26 with consolidated revenue of ₹2,265 crore (+17.5% YoY) and EBITDA margin expansion of 290 bps to 22.3%, driven by hospital business growth of 19.4% and diagnostics margin recovery to 23.1%. PAT declined to ₹197 crore due to a one-off expense of ₹55 crore for new labor codes. Hospital occupancy remained steady at 67%, while ARPOB grew 4.5% to ₹2.56 lakh, supported by a 52% surge in robotic surgeries. The diagnostics business saw 8.3% revenue growth and a 870 bps margin improvement. Management guided for continued growth trajectory with brownfield expansion of ~400 beds in FY27, led by the fMRI facility. The People Tree acquisition in Bengaluru adds 125 beds with expansion potential to 300. Risks include integration challenges at Glenagles and potential dilution from IHH's planned equity infusion.
Key Numbers
ARPOB
₹2.56 lakh
+4.5% YoY
Growth driven by case mix shift to complex procedures, including 52% rise in robotic surgeries.
Diagnostics Volume
9.9M tests
+3.6% YoY
Volume growth supported by network expansion of 175 touch points in Q3.
Bed Addition (9M FY26)
750 beds
+500 beds via M&A, +250 organic
Includes People Tree acquisition (125 beds) and brownfield expansions at Manesar, Noida, Faridabad.
Management Guidance
Brownfield bed addition of ~400 beds in FY27
Major contribution from fMRI expansion (200+ beds) to be commissioned in phases starting April 2026.
expansionARPOB growth of 4-5% annually for next 2 years
Driven by ~2.5% price increase and balance from case mix improvement, especially in oncology.
growthContinued margin improvement trajectory for at least 2 years
Supported by brownfield expansions in high-margin facilities like fMRI and operational leverage.
marginsPotential equity infusion by IHH within 3-6 months
Preferential allotment likely after cooling period ends in May 2026, to strengthen balance sheet for growth.
otherKey Risks
Glenagles integration challenges
Revenue declined 4% in 9M FY26 due to management changes and operational issues; turnaround expected only from next fiscal.
high · analyst_questionIntense competition in Hyderabad cluster
Management expressed caution about Hyderabad due to competitive intensity, though it remains a focus cluster.
medium · management_commentaryExecution risk in People Tree ramp-up
Acquired hospital is suboptimal and requires investment; expansion to 300 beds may take 30 months due to Bangalore approval delays.
medium · management_commentaryCGHS/ECHS rate hike benefits uncertain
New circulars have implementation ambiguities; full benefit may be delayed until clarity on super-specialty rates and drug pricing.
low · management_commentaryNotable Quotes
Our business performance in Q3 has been good considering the seasonal impact of festivals in some of our key geographies.
We feel there is still scope for margin improvement especially with the brownfield expansion.
We are doing acquisition opportunity in the existing cluster itself. We feel we have a very strong brand equity in whichever cluster we present.